Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of standard-of-care osteoporosis management after BA058 treatment
2012-002216-10Phase 3Completed
- Sponsor
- Radius Health Inc
- Start
- Sep 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of abaloparatide and alendronate in osteoporosis (2 arms), sponsored by Radius Health Inc. Primary endpoint: Safety of alendronate after BA058/placebo. Started Sep 2012; status: completed.
02
Drugs
abaloparatidealendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2012-002216-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002216-10.